STOCK TITAN

BiomX (PHGE) Stock News, Jan-Mar 2021

PHGE NYSE

Ticker history: PHGE became HLSQ (Tessera Defense and Homeland Security Inc.) on .

Historical ticker: BiomX Inc. changed its name to Tessera Defense and Homeland Security Inc. and began trading as HLSQ on September 11, 2026. PHGE news and SEC filings are retained here with their original names and dates. The profile below describes the earlier BiomX business.

BiomX Inc. (PHGE) news is centered on the company’s transition from a legacy phage therapy profile toward defense, security, critical infrastructure, and first-response technologies. Recent company announcements focus heavily on Zorronet, an AI defense technology subsidiary that develops command-and-control, computer vision, and autonomous surveillance systems.

PHGE news can include acquisition updates, material agreements, customer deployments, and operating details tied to Zorronet and DFSL. Zorronet-related coverage has included AI command-and-control software, secure on-premise and hybrid C5ISR deployments, mobile field-operator tools, and the use of cameras, sensors, drones, and IoT devices in integrated security environments.

Infrastructure and government-related items are also important for BiomX coverage. Company disclosures have discussed Zorronet’s work with Israel Railways, contracts with the Israel Defense Forces, and engagements involving government customers, Tier-1 OEMs such as Elbit Systems, and international clients. DFSL adds another news angle through LADAR-based detection systems for perimeter security, critical infrastructure, and counter-UAS markets.

BiomX news may also include SEC filing events, shareholder votes, governance changes, capital-structure disclosures, and operating results. Because the company has disclosed substantial doubt about its ability to continue as a going concern, financing and liquidity-related disclosures are also material to PHGE coverage. For investors tracking PHGE, the main news themes are defense technology acquisitions, operational deployments, critical infrastructure agreements, and the company’s remaining phage therapy background.

Rhea-AI Summary

BiomX (NYSE American: PHGE) plans to host a conference call on March 31, 2021, at 8:00 a.m. EDT to discuss its fourth quarter and full year 2020 financial results. The call will be accessible via phone and an archived webcast will be available on their website. BiomX specializes in developing phage therapies targeting pathogenic bacteria linked to skin conditions and chronic diseases, including inflammatory bowel disease and colorectal cancer. Their innovations focus on creating customized phage cocktails to effectively combat these bacterial targets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.20%
Tags
conferences earnings
-
Rhea-AI Summary

BiomX (NYSE American: PHGE) has initiated a Phase 2 clinical study for BX001, a topical gel aimed at treating mild-to-moderate acne. The trial, involving 140 participants, will evaluate the safety and efficacy of BX001 over 12 weeks. This significant step follows promising Phase 1 results, which showed a statistically significant reduction in C. acnes levels compared to placebo. Results from the interim 8-week assessment are anticipated in Q3 2021, with comprehensive results expected in Q4 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.77%
Tags
-
Rhea-AI Summary

BiomX (NYSE American: PHGE), a clinical-stage biotechnology company, announced that CEO Jonathan Solomon will present at two virtual investor conferences in March 2021. The first event is Chardan’s 3rd Annual Microbiome Medicines Summit on March 8, 2021, at 10:45 AM EST. The second is H.C. Wainwright's Global Life Sciences Conference on March 9, 2021, with on-demand access starting at 7:00 AM EST. The presentations will be available for streaming on the company’s website, offering insights into BiomX's development of phage therapies targeting specific pathogenic bacteria.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.29%
Tags
conferences
Rhea-AI Summary

BiomX Inc. (PHGE) announced positive results from its first-in-human Phase 1a study of BX002, an orally administered phage therapy targeting Klebsiella pneumoniae. The study demonstrated BX002 is safe and well-tolerated, with no serious adverse events. It successfully delivered high concentrations of viable phages, approximately 1010 PFU, significantly exceeding bacterial burden in patients. Following these results, BiomX plans to advance to a Phase 1b/2a study for BX003 aimed at reducing K. pneumoniae in targeted individuals, with results expected by mid-2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.26%
Tags
-
Rhea-AI Summary

BiomX (NYSE American: PHGE), a clinical-stage biotechnology company, has announced that CEO Jonathan Solomon will participate in two upcoming investor conferences. The H.C. Wainwright BioConnect Conference is scheduled for January 11-14, 2021, with a playback available at 6 a.m. EST on January 11. Additionally, the Oppenheimer Virtual Banking Meeting will occur during the same dates with one-on-one meetings only. BiomX focuses on developing natural and engineered phage therapies targeting bacteria affecting skin health and chronic diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.10%
Tags
conferences

FAQ

What is the current stock price of BiomX (PHGE)?

BiomX (PHGE) last closed at $1.85. The company now trades as HLSQ.